Meeting Report

Workshop on Ataxia-Telangiectasia Heterozygotes and Cancer

There is a common misconception that genetically controlled cancer proneness is synonymous with familial cancer. In fact, there is increasing evidence that cancer-predisposing genes are present in the population at frequencies which may significantly affect cancer incidence yet which do not result in cancer with a high enough probability to give rise to "cancer families." One example may be a gene predisposing smokers to lung cancer which has been suggested to be associated with the gene for debrizoquine metabolism (1). Another example, on which much more information is available, is the autosomal recessive genes for A-T2 in the heterozygous (i.e., carrier) state, which was the main subject of this informal workshop.

Homozygotes for A-T show a rare syndrome with a fascinating variety of aspects. Patients are deficient in immune response, show progressive neurological degeneration and defects in organ maturation, and are prone to develop cancer, particularly of the cells of the immune system (see Ref. 2). Their cells show spontaneous chromosomal instabilities, and there are reports of hypersensitivity to the chromosome-breaking and/or lethal effect of ionizing radiation and certain chemicals such as bleomycin, neocarzinostatin, Adriamycin, and Hoechst 33342. A further addition to this list is phorbol ester (Shiloh, Boston, MA), a tumor promoter that has been claimed to cause endogenous production of free radicals. Such experimental evidence as exists suggests that A-T homozygotes have a defect in the processing (repair?) of DNA that has experienced free radical attack.

In contrast to homozygotes, A-T heterozygotes (found in high proportion among close blood relatives of homozygotes) appear to be normal members of the population. They became of interest, however, following the first study in the USA by Swift (3) which suggested that they too may be cancer prone. A second, more broadly based study by Swift (N. Carolina) is still in progress, but the results to date (based on 225 homozygotes in 140 families) appear to be consistent with the general conclusion of the first study. There is a clear need for information from other populations. An MRC-funded study in the United Kingdom, currently with 58 homozygotes in 52 families, may help but linkage of the data with other studies not yet started may prove to be essential if independent confirmation is to be achieved in a reasonable time period. The currently available data do not enable risk estimates to be made with any confidence for individual types of cancer, but it is clear that the spectrum of cancers among the relatives of homozygotes is different from that of the A-T homozygotes. A speculative explanation is that the profound immunodeficiency of the homozygotes influences the relative incidence of different cancers.

How frequent are A-T heterozygotes in the general population? Swift's current study suggests an incidence of homozygotes of at least 3 per 106 live births, but ascertainment is almost certainly incomplete. The highest figure is in Pennsylvania and Michigan (around 8 to 10 per 106 live births). An independent estimate of one in 105 may be made from the frequency of homozygous cousins of homozygous probands with A-T (assuming an outbred population). The United Kingdom study using cases born between 1969 and 1976 also yields a frequency of around 1 per 105 (but not all birth dates are yet known and ascertainment is also probably incomplete). The incidence of heterozygotes may be calculated from the same data if one makes assumptions about the number of genes involved and their relative frequency. The consensus view was that 1 to 2% of the population was the most likely frequency of A-T heterozygotes.

The number of genes involved is actually one of the weaker pieces of information. Five or conceivably 9 complementation groups may have been identified, but 4 different techniques have been used, and there has been almost no overlap in the cell strains used thus preventing cross-validation. From experience with other diseases such as xeroderma pigmentosum, it would seem likely that a number of other complementation groups remain to be discovered.

The outcome of the epidemiological studies currently in progress is likely to be of importance. An appreciably elevated cancer risk in A-T heterozygotes would have significant consequences for cancer epidemiology and public health. It must be emphasized...
that there is no direct evidence that enhanced cancer incidence in heterozygotes is a consequence of a greater susceptibility to DNA damage by exogenous agents such as ionizing radiation, although chromosomal damage in their cultured cells of heterozygotes does show such a susceptibility. If it were to be so, however, there would be a number of important ethical problems to be faced in areas as diverse as radiation protection, carcinogen risk assessment, and genetic counseling.

References
1. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (Lond.), 312: 169-170, 1984.
2. Gatti, R. A. Ataxia-telangiectasia: immune dysfunction is one of many defects. Immunol. Today, 5: 121-123, 1984.
3. Swift, M. Disease predisposition of ataxia-telangiectasia heterozygotes. In: B. A. Bridges and D. G. Hamden (eds.), Ataxia-Telangiectasia—a Cellular and Molecular Link between Cancer, Neuropathology and Immune Deficiency, pp. 355-361. Chicester, England: John Wiley & Sons, Inc., 1982.
Workshop on Ataxia-Telangiectasia Heterozygotes and Cancer

B. A. Bridges, G. Lenoir and L. Tomatis

Cancer Res 1985;45:3979-3980.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/45/8/3979.citation

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.